Paratek Pharmaceuticals (PRTK) Doses First Patient in Phase 3 Study of Oral-only Omadacycline in ABSSSI
Go back to Paratek Pharmaceuticals (PRTK) Doses First Patient in Phase 3 Study of Oral-only Omadacycline in ABSSSI| Profile Technologies, Inc. (NASDAQ: PRTK) | Delayed: 2.23 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.23 | 52 Week High | $22.00 | |||
| Open | $2.23 | 52 Week Low | $9.80 | |||
| Day High | $2.23 | P/E | N/A | |||
| Day Low | $2.23 | EPS | $-0.08 | |||
| Volume | 1,277,025 | |||||
